Navigation Links
Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
Date:8/19/2007

ystar Bio-Pharmaceutical Company is a China-based producer and distributor of veterinary medication, vaccines, micro-organisms and 100% organic herbal feed additives to cure and prevent disease in poultry, livestock, birds and pets. The company's product line consists of more than 80 state-of-the-art products with over 50 additional products in the developmental stage. Skystar has formed strategic sales distribution networks throughout China. Skystar recently completed construction of new state-of-the- art Bio-Pharmaceutical facilities covering an area of almost eight acres. The new facilities meet or exceed all Good Manufacturing Practice (GMP) Certification Standards and have received GMP Certification from the Chinese government. For additional information, please visit http://www.skystarbio-pharmaceutical.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995:

Certain statements in this press release and oral statements made by Skystar on its conference call in relation to this release, constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors include, but are not limited to uncertainties in product demand, the impact of competitive products and pricing, the Company's ability to obtain regulatory approvals, changing economic conditions around the world, release and sales of new products and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, fu
'/>"/>

SOURCE Skystar Bio-Pharmaceutical Co.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... ... supplier, announces the launch of their 2nd generation cell therapy POD® design. The ... CT, but it also represents a new POD® design. , “G-CON first ...
(Date:7/29/2015)... 2015  AmnioChor Inc., an early stage biotech startup ... to announce that the Musculoskeletal Transplant Foundation of ... in their seed round of development of the proprietary ... AmnioChor,s technology allows cryopreservation of the ... cells living within those tissues. Amnion is a well-established ...
(Date:7/29/2015)... 2015  Indivior PLC (LON: INDV) today announced that ... was accepted and received Priority Review by the U.S. ... opioid overdose. This naloxone nasal spray comes as a ... absorption into the nasal mucosa. 1 The device ... may be better equipped to help an opioid overdose ...
(Date:7/29/2015)... QUEBEC CITY , July 29, 2015 /PRNewswire/ ... (the "Company") today announced it has selected an optimized ... important milestone in the development of a new ... The MAPK pathway represents a prime target for ... significant antitumor activities and survival benefits for B-Raf ...
Breaking Biology Technology:G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... N.J., June 23 SyntheMed, Inc. (OTC Bulletin Board: ... commercialization of anti-adhesion products, announced today that the company ... Health Innovation Award in pediatrics. The company ... & Sullivan medical device analysts in recognition of the ...
... CHICAGO, June 23 Advanced Life Sciences Holdings, Inc. ... non-human primate study involving its novel, once-a-day, oral antibiotic ... achieved a 100% survival rate against an inhaled lethal ... study that received 16 mg/kg once-a-day (the human equivalent ...
... to Double 2009 Grant Awards to Nearly $4 Million ... The Lustgarten Foundation, the nation,s largest private supporter of pancreatic ... totaling $1.6 million awarded to six leading research centers for ... nation,s deadliest cancers. , , Lustgarten is expected ...
Cached Biology Technology:SyntheMed Receives Frost & Sullivan Health Innovation Award Nomination 2Advanced Life Sciences' Restanza(TM) Shows 100% Survival In Confirmatory Anthrax Study 2Advanced Life Sciences' Restanza(TM) Shows 100% Survival In Confirmatory Anthrax Study 3The Lustgarten Foundation Awards Six Research Centers With Pancreatic Cancer Research Funding 2
(Date:7/13/2015)... , Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION ... new convenient and secure method to make payments.  ... payment methods, introduced with its groundbreaking voice-direct payment ...
(Date:7/8/2015)... 2015 Summary Pancreatic cancer is the ... fatal, with a mortality rate of 10.9 deaths per ... cancer patients has highlighted a significant need for new ... met by the current market. A highly active ... varying molecule types and mechanisms of action, which provides ...
(Date:7/7/2015)... , July 7, 2015  Based on ... Frost & Sullivan recognizes Credence ID, LLC with ... Entrepreneurial Company of the Year Award. Credence ID ... aid in its mission of offering enrollment and ... globally. As Credence ID was formed by experts ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... weekend warriors: the simple act of exercise and not ... a new University of Florida study finds. People ... gaining strength or boosting cardiovascular fitness feel just as ... said Heather Hausenblas, a UF exercise psychologist. Her study ...
... sees the launch of Ensembl Plants a ... by the European Molecular Biology Laboratory,s European ... Spring Harbor Laboratory, USA. Ensembl Plants allows researchers ... genome-scale experiments in different plant species. By pinpointing ...
... disease and other diet related health problems received a 4 ... projects. The projects, taking place in universities and research institutes ... publicly-funded Research Councils and 15 companies. This means the research ... in our society but in a way that the food ...
Cached Biology News:UF study: Exercise improves body image for fit and unfit alike 2UF study: Exercise improves body image for fit and unfit alike 3New portal for plant genomics will support research into improved crops 2Public sector and industry unite to attack obesity and heart disease 2
... Rabbit polyclonal to Ki67 - Proliferation Marker, ... cell cycle related nuclear protein, expressed by ... active cell cycle (G1, S, G2 and ... (G0) cells. Ki67 antibodies are useful in ...
Rabbit polyclonal to Shigella (HRP) ( Abpromise for all tested applications)....
HLA II DG+DR+DP Monoclonal Antibody, Purified, Unconjugated, Clone: IQU9 This antibody is specific for the monomorphic determinant of the HLA Class II beta chains of the human MHC (28 kDa)....
100 g monoclonal antibody which can immunocapture ~10 g of Complex IV from heart mitochondria. Also included are 2 mg of bovine heart mitochondria for control immunocapture....
Biology Products: